Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics

BACKGROUND: Patients with schizophrenia struggle with disease relapses and uncontrolled symptoms, which can either result in or be a result of non-adherence to antipsychotics (APs). The economic burden of such patients is hypothesized to be substantial. OBJECTIVE: To evaluate the economic burden of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilon, Dominic, Patel, Charmi, Lafeuille, Marie-Hélène, Zhdanava, Maryia, Lin, Dee, Côté-Sergent, Aurélie, Rossi, Carmine, Lefebvre, Patrick, Joshi, Kruti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391021/
https://www.ncbi.nlm.nih.gov/pubmed/34185557
http://dx.doi.org/10.18553/jmcp.2021.27.7.904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391021/
https://www.ncbi.nlm.nih.gov/pubmed/34185557
http://dx.doi.org/10.18553/jmcp.2021.27.7.904

Ejemplares similares